Marcelo Rosandiski Lyra Selected Research

Meglumine Antimoniate

1/2024	Self-reporting of hearing loss and tinnitus in the diagnosis of ototoxicity by meglumine antimoniate in patients treated for American tegumentary Leishmaniasis.
6/2023	Is There Any Difference in the In Situ Immune Response in Active Localized Cutaneous Leishmaniasis That Respond Well or Poorly to Meglumine Antimoniate Treatment or Spontaneously Heal?
1/2021	An old drug and different ways to treat cutaneous leishmaniasis: Intralesional and intramuscular meglumine antimoniate in a reference center, Rio de Janeiro, Brazil.
11/2018	Favorable responses to treatment with 5 mg Sbv/kg/day meglumine antimoniate in patients with American tegumentary leishmaniasis acquired in different Brazilian regions.
12/2017	Low dose systemic or intralesional meglumine antimoniate treatment for American tegumentary leishmaniasis results in low lethality, low incidence of relapse, and low late mucosal involvement in a referral centre in Rio de Janeiro, Brazil (2001-2013).
3/2017	Intralesional treatment with meglumine antimoniate in three patients with New World cutaneous leishmaniasis and large periarticular lesions with comorbidities.
11/2016	Standardization of intralesional meglumine antimoniate treatment for cutaneous leishmaniasis.
9/2016	PANCREATIC TOXICITY AS AN ADVERSE EFFECT INDUCED BY MEGLUMINE ANTIMONIATE THERAPY IN A CLINICAL TRIAL FOR CUTANEOUS LEISHMANIASIS.
7/2014	Factors associated to adherence to different treatment schemes with meglumine antimoniate in a clinical trial for cutaneous leishmaniasis.
3/2011	American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis resistant to meglumine antimoniate, but with good response to pentamidine: a case report.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Marcelo Rosandiski Lyra Research Topics

Disease

10	Cutaneous Leishmaniasis 06/2023 - 03/2011
3	Leishmaniasis 01/2024 - 12/2017
2	Sporotrichosis 03/2021 - 11/2014
2	Mycetoma 01/2017 - 03/2015
1	Tinnitus 01/2024
1	Hearing Loss (Hearing Impairment) 01/2024
1	Ototoxicity 01/2024
1	Communicable Diseases (Infectious Diseases) 12/2017
1	HIV Infections (HIV Infection) 11/2014
1	Blister (Bulla) 12/2012
1	Porphyria Cutanea Tarda 12/2012
1	Herpes Simplex Encephalitis (Herpes Encephalitis) 11/2011

Drug/Important Bio-Agent (IBA)

10	Meglumine AntimoniateIBA 01/2024 - 03/2011
2	Terbinafine (Lamisil)FDA LinkGeneric 03/2021 - 01/2017
2	Itraconazole (Sporanox)FDA LinkGeneric 03/2021 - 01/2017
1	Potassium Iodide (Pima)FDA Link 03/2021
1	Trimethoprim (Proloprim)FDA LinkGeneric 01/2017
1	AntimonyIBA 01/2017
1	Sulfamethoxazole FDA LinkGeneric 01/2017
1	Amphotericin B (Amphotericin)FDA LinkGeneric 01/2017
1	Amikacin (A.M.K)FDA LinkGeneric 01/2017
1	Fluconazole (Zonal)FDA LinkGeneric 01/2017
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 08/2015
1	Adrenal Cortex Hormones (Corticosteroids)IBA 11/2014
1	Uroporphyrinogen Decarboxylase (Uroporphyrinogen III Decarboxylase)IBA 12/2012
1	4 alpha-glucanotransferaseIBA 12/2012
1	Acyclovir (Aciclovir)FDA LinkGeneric 11/2011
1	Methylprednisolone FDA LinkGeneric 11/2011
1	Pentamidine (NebuPent)FDA LinkGeneric 03/2011

Therapy/Procedure

3	Therapeutics 03/2017 - 02/2015
2	Surgical Amputation (Amputations) 01/2017 - 03/2015
1	Cryosurgery 03/2021
1	Complementary Therapies (Alternative Medicine) 12/2017
1	Intralesional Injections 03/2017
1	Operative Surgical Procedures 01/2017
1	Highly Active Antiretroviral Therapy (HAART) 12/2012